The Immunization Record is available to download from the Health Insurance and Immunizations website at [drexel.edu/hii/forms](drexel.edu/hii/forms).

**To ensure the safety of all students, Drexel requires all full-time students to have up-to-date immunizations.**

### Completing Your Immunization Record

1. You must return the Tuberculosis Screening Questionnaire with your Immunization Record or your forms will not be processed.
2. All students must complete all of Part 1 of the Immunization Record (this form is located on the following page) and sign Part 3.
3. Part 2 of the Immunization Record is completed by your health care provider and they must sign where indicated.
4. All students must complete Part I of the Tuberculosis Screening Questionnaire (follows the Immunization Record in this guide) and your health care provider must complete Part II.
5. All blood tests require titer lab reports to be attached in English.
6. Upload only completed forms via DrexelOne, as incomplete forms will be discarded.

### IMMUNIZATION POLICY

Drexel University requires all entering domestic full-time undergraduate and graduate students to complete an Immunization Record.

All full- and part-time international students (including all visa holders and permanent residents) are also required to complete an Immunization Record.

*Please note:* A $35 immunization processing fee is required of all students regardless of where they received their vaccines. This fee will be posted on the student's bill.

Students at the University City Campus, please email [healthimmu@drexel.edu](mailto:healthimmu@drexel.edu) with questions.

Students at the Center City and Queen Lane campuses, please email [vaccinescnhp@drexel.edu](mailto:vaccinescnhp@drexel.edu) with questions.

*Online students are not required to complete an Immunization Record.*

### Submission Process for All Students

All students must upload completed Immunization Records using the “Immunization Record” channel on the Welcome tab via DrexelOne at [one.drexel.edu](http://one.drexel.edu). Upload instructions can be found at [drexel.edu/hii/immunizations](drexel.edu/hii/immunizations). Please refer back to DrexelOne 48–72 hours after uploading to check the status.

### Additional Requirements

Visit [drexel.edu/cnhp/about/compliance/programspecific](drexel.edu/cnhp/about/compliance/programspecific) to view your program-specific requirements and to download the CNHP immunization forms, which we will accept and can be uploaded to DrexelOne. If you have any questions, email [cnhpcompliance@drexel.edu](mailto:cnhpcompliance@drexel.edu).
PART 2: TO BE COMPLETED AND SIGNED BY YOUR HEALTH CARE PROVIDER.

A. TUBERCULOSIS – PLEASE SEE ATTACHMENT 1 TO COMPLY WITH THIS REQUIREMENT. ALL STUDENTS MUST UPLOAD PART 1 ALONG WITH THIS FORM

B. TDAP - Required within last 10 years.
All students must have proof of Tdap dated 2005 or later. Td does not satisfy this requirement. Td booster is required if Tdap is older than 10 years

TDAP: Td:

C. MMR (Measles, Mumps, Rubella) - Two doses of vaccine OR blood test showing immunity COPY OF LAB REPORT REQUIRED.

1st dose date: 2nd dose date (minimum of four weeks after dose 1):

D. VARICELLA (Chicken Pox) Complete ONE of the following: history of disease, OR two doses of vaccine OR blood test showing immunity COPY OF LAB REPORT IS REQUIRED.

History of disease: ___Yes ___No OR Vaccination 1st dose date Vaccination 2nd dose date (minimum of four weeks after dose 1): _______

E. HEPATITIS B - Completion of at least two of three required for compliance (three doses required to complete the series) OR blood test showing immunity COPY OF LAB REPORT REQUIRED.

Vaccination 1st dose date: Vaccination 2nd dose date (minimum of four weeks after dose 1): Vaccination 3rd dose date (minimum of eight weeks after dose 2 and a minimum of 16 weeks after dose 1):

F. MENINGOCOCCAL - Required for all full-time undergraduate students age 21 or younger and all students living in University housing. Meningococcal Quadrivalent: (MCV4, such as Menactra or Menveo) since age 16

Quadrivalent conjugate (circle one): Date given:
Menactra Menveo

G. HEALTH CARE EXAMINER’S STATEMENT: I HAVE VERIFIED THAT THE INDIVIDUAL I HAVE EXAMINED IS THE NAMED INDIVIDUAL ON THIS FORM AND THAT THE ABOVE TESTS/VACCINATIONS WERE PERFORMED IN THIS OFFICE/LABORATORY, OR I HAVE REVIEWED ANY DOCUMENTATION RELATIVE TO THE STUDENT’S IMMUNIZATION RECORD

License #: Phone:
Signature of Healthcare Examiner: Date:

PART 3: TO BE SIGNED BY THE STUDENT - FORM CANNOT BE PROCESSED WITHOUT STUDENT SIGNATURE.

Student Signature Student ID# (8 digits)

The information provided on this form is correct. I understand that failure to complete this form correctly may jeopardize my student standing at Drexel University. I will submit the form using the directions provided on information sheet. College of Nursing and Health Professions: I understand that this form meets University requirements, however, there are additional program requirements that must also be satisfied. I will access them at drexel.edu/cnhp/about/compliance/complianceforms and forward them to my program.
TOOL FOR INSTITUTIONAL USE

Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following questions:

1: Have you ever had close contact with persons known or suspected to have active TB disease?  □ Yes □ No

2: Were you born in one of the countries or territories listed below that have a high incidence of active TB disease?  □ Yes □ No

(If yes, please CIRCLE the country, below)

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>Dominican Republic</td>
<td>Malaysia</td>
<td>Sao Tome and Principe</td>
</tr>
<tr>
<td>Algeria</td>
<td>Ecuador</td>
<td>Maldives</td>
<td>Senegal</td>
</tr>
<tr>
<td>Angola</td>
<td>El Salvador</td>
<td>Mali</td>
<td>Serbia</td>
</tr>
<tr>
<td>Anguilla</td>
<td>Equatorial Guinea</td>
<td>Marshall Islands</td>
<td>Sierra Leone</td>
</tr>
<tr>
<td>Argentina</td>
<td>Eritrea</td>
<td>Mauritania</td>
<td>Singapore</td>
</tr>
<tr>
<td>Armenia</td>
<td>Ethiopia</td>
<td>Mauritius</td>
<td>Solomon Islands</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>Fiji</td>
<td>Mexico</td>
<td>Somalia</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>Gabon</td>
<td>Micronesia (Federated States of)</td>
<td>South Africa</td>
</tr>
<tr>
<td>Belarus</td>
<td>Gambia</td>
<td>Myanmar</td>
<td>Syrian Arab Republic</td>
</tr>
<tr>
<td>Belize</td>
<td>Georgia</td>
<td>Mongolia</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Benin</td>
<td>Ghana</td>
<td>Montenegro</td>
<td>Sudan</td>
</tr>
<tr>
<td>Bhutan</td>
<td>Greenland</td>
<td>Morocco</td>
<td>Suriname</td>
</tr>
<tr>
<td>Bolivia (Plurinational State of)</td>
<td>Guam</td>
<td>Mozambique</td>
<td>Swaziland</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>Guatemala</td>
<td>Myanmar</td>
<td>Syrian Arab Republic</td>
</tr>
<tr>
<td>Botswana</td>
<td>Guinea</td>
<td>Namibia</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>Brazil</td>
<td>Guinea-Bissau</td>
<td>Nauru</td>
<td>Tanzania (United Republic of)</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Guyana</td>
<td>Nepal</td>
<td>Thailand</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Haiti</td>
<td>New Caledonia</td>
<td>Timor-Leste</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>Honduras</td>
<td>Nicaragua</td>
<td>Togo</td>
</tr>
<tr>
<td>Burundi</td>
<td>India</td>
<td>Niger</td>
<td>Tunisia</td>
</tr>
<tr>
<td>Cabo Verde</td>
<td>Indonesia</td>
<td>Nigeria</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Iraq</td>
<td>Northern Mariana Islands</td>
<td>Tuvalu</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Kazakhstan</td>
<td>Pakistan</td>
<td>Uganda</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>Kenya</td>
<td>Palau</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Chad</td>
<td>Kiribati</td>
<td>Panama</td>
<td>Uruguay</td>
</tr>
<tr>
<td>China</td>
<td>Kuwait</td>
<td>Papua New Guinea</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>China, Hong Kong SAR</td>
<td>Kyrgyzstan</td>
<td>Paraguay</td>
<td>Vanuatu</td>
</tr>
<tr>
<td>China, Macao SAR</td>
<td>Lao People’s</td>
<td>Peru</td>
<td>Venezuela (Bolivarian Republic of)</td>
</tr>
<tr>
<td>Colombia, Comoros</td>
<td>Democratic Republic</td>
<td>Philippines</td>
<td></td>
</tr>
<tr>
<td>Congo</td>
<td>Latvia</td>
<td>Portugal</td>
<td></td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>Lesotho</td>
<td>Qatar</td>
<td>Yemen</td>
</tr>
<tr>
<td>Democratic People’s Republic of Korea</td>
<td>Liberia</td>
<td>Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>Lithuania</td>
<td>Republic of Moldova</td>
<td></td>
</tr>
<tr>
<td>Djibouti</td>
<td>Malawi</td>
<td>Russian Federation</td>
<td>Taiz</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rwanda</td>
<td></td>
</tr>
</tbody>
</table>

Source: World Health Organization Global Health Observatory, Tuberculosis Incidence 2015. Countries with incidence rates of 20 cases per 100,000 population. For future updates, refer to who.int/tb/country/data/profiles.

3: Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease?  □ Yes □ No

4: Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?  □ Yes □ No

5: Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?  □ Yes □ No

6: Have you ever been a member of any of the following groups that may have an increased incidence of latent M. tuberculosis infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?  □ Yes □ No

If the answer is YES to any of the above questions, Drexel University requires that you receive TB testing as soon as possible but at least prior to the start of the subsequent semester).

If the answer to all of the above questions is NO, no further testing or further action is required.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.

Student Signature: ___________________________  Date: ___________________________
Part II. Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either the Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

- History of a positive TB skin test or IGRA blood test? (If yes, document below.) □ Yes □ No
- History of BCG vaccination? (If yes, consider IGRA if possible.) □ Yes □ No

1. TB SYMPTOM CHECK
Does the student have signs or symptoms of active pulmonary tuberculosis disease?

□ Yes □ No

If No, proceed to 2 or 3.

If yes, check below:

- Cough (especially if lasting for 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- Chest pain
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Fever

Proceed with additional evaluation to exclude active tuberculosis disease, including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. TUBERCULIN SKIN TEST (TST), WHICH MUST BE PERFORMED IN THE UNITED STATES
(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0.” The TST interpretation should be based on mm of induration as well as risk factors.)**

Date Given: ____/____/____ Date Read: ____/____/____
M       D          Y                             M       D          Y
Result: ________ mm of induration           **Interpretation:  positive____ negative____

Date Given: ____/____/____ Date Read: ____/____/____
M       D          Y                             M       D          Y
Result: ________ mm of induration           **Interpretation:  positive____ negative____

**INTERPRETATION GUIDELINES

>5 mm is positive:
- recent close contacts of an individual with infectious TB
- persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month)
- HIV-infected persons

>10 mm is positive:
- recent arrivals to the U.S. (<5 years) from high-prevalence areas or who resided in one for a significant* amount of time
- injection drug users
- mycobacteriology laboratory personnel
- residents, employees, or volunteers in high-risk congregate settings
- persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:
- persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.
3. INTERFERON GAMMA RELEASE ASSAY (IGRA)

Date Obtained: _____/_____/_____  (specify method)  QFT-GIT  T-Spot  other_____  
M  D  Y
Result: negative___  positive___  indeterminate___  borderline___ (T-Spot only)

Date Obtained: _____/_____/_____  (specify method)  QFT-GIT  T-Spot  other_____  
M  D  Y
Result: negative___  positive___  indeterminate___  borderline___ (T-Spot only)

4. CHEST X-RAY: (REQUIRED IF TST OR IGRA IS POSITIVE, AND MUST BE PERFORMED IN THE UNITED STATES)

Date of chest x-ray: _____/_____/_____  Result: normal____  abnormal____  
M  D  Y

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

• Infected with HIV
• Recently infected with M. tuberculosis (within the past 2 years)
• History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
• Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
• Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
• Have had a gastrectomy or jejunoileal bypass
• Weigh less than 90% of their ideal body weight
• Cigarette smokers and persons who abuse drugs and/or alcohol

☐ Student agrees to receive treatment

☐ Student declines treatment at this time

Health Care Professional Signature ____________________________________________  Date ____________________